Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca

This article was originally published in The Tan Sheet

Executive Summary

U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)

You may also be interested in...



AstraZeneca Prilosec OTC Launch Anticipated For Second Quarter 2001

AstraZeneca's Prilosec proton pump inhibitor is anticipated to reach over-the-counter shelves in the second quarter of 2001.

AstraZeneca Prilosec OTC Launch Anticipated For Second Quarter 2001

AstraZeneca's Prilosec proton pump inhibitor is anticipated to reach over-the-counter shelves in the second quarter of 2001.

AstraZeneca Prilosec OTC Launch Anticipated For Second Quarter 2001

AstraZeneca's Prilosec proton pump inhibitor is anticipated to reach over-the-counter shelves in the second quarter of 2001.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel